1、Executive PerspectivesDecember 2025BiopharmaThe Future of Biopharma with E2E AI Transformation2Copyright 2025 by Boston Consulting Group.All rights reserved.IntroductionWe meet often with CEOs to discuss AI-a topic that is both captivating and rapidly changing.After working with over 2,000 clients i
2、n the past 2+years,we are sharing our most recent learning in a new series designed to help CEOs navigate AI.With most sectors going through major shifts,the focus in 2025 is on how to leverage AI to fully transform organizations and create new sources of competitive advantage.In this edition,we dis
3、cuss the future of Biopharma and the role AI will play in turbocharging growth.We address key questions on the minds of Biopharma executives:How can AI reshape competitiveness in Biopharma?What does it mean to operate as an AI-first enterprise end-to-end?How are leading players creating value with A
4、I today?What pragmatic steps should I take to scale impact?This document is a guide for Biopharma executives to cut through the hype around AI and understand what creates value now and in the future.In this BCG Executive Perspective,we articulate the vision and value of the future of Biopharma with
5、AI3Copyright 2025 by Boston Consulting Group.All rights reserved.Executive summary|The future of Biopharma with E2E AI transformationWHY now is the right time to actWHAT leading Biopharma companies are doing to create value leveraging AIHOW to start the journey to become an AI-first enterprise Marke
6、t pressures require transformations across R&D,ops,and commercial;rising R&D costs and longer timelines are unsustainable;AI has already shown it can cut discovery from 4-5 years to 8 months and accelerate trials by 20%AI is now a proven enterprise enabler;beyond pilots,scaled use is driving+23%yiel
0731-84720580
商务合作：really158d
研搜
微信扫码登录
手机快捷登录
账号登录
